Gout
Conditions
Interventions
Observation group:none
Sponsors
Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. No gender or age restrictions; 2. The researcher diagnosed gout based on the 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) gout classification criteria and planned to receive anti-gout drug treatment; 3. According to the "Diagnosis and Treatment Standards for Gout" released by the Rheumatology Branch of the Chinese Medical Association in 2023, the disease status is classified as follows: The acute stage is defined as the sudden onset of typical symptoms and signs of gout acute stage such as redness, swelling, heat and pain in the first metatarsophalangeal, ankle, dorsus of the foot and knee joints within 2 weeks before enrollment. The intermission period is defined as the non-acute period, that is, the patient has no acute gout attack within 2 weeks before enrollment; 4. Possess and be able to use a smart phone, and agree to conduct remote follow-up data reporting through the research mini-program; 5. Be able to understand the research process and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. There is a known hypersensitivity reaction to anti-gout drugs or any of their excipients; 2 Patients who have been diagnosed with diseases that seriously threaten their survival and have an expected survival period of less than one month; 3 Participate in any interventional clinical trials; 4 Other conditions that the researcher deems unsuitable for participation in this study (such as poor patient compliance, mental illness, pregnant or lactating patients, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change value of the visual Analogue Scale (VAS) score on the 7th day after treatment compared with the baseline;Pain relief time;The number of gout attacks within 3, 6, and 12 months after treatment;The proportion of patients without gout attacks within 12 months after treatment;The incidence of adverse events (AE) and serious adverse events (SAE); | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in uric acid levels from baseline 12 months after treatment;The changes in the overall patient assessment (PGA) score from baseline at 3, 6, and 12 months after treatment; | — |
Countries
China
Contacts
Public ContactZhang Liyun
Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences)
Outcome results
None listed